MicroRNAs (miRNAs) are a small functional non-coding RNAs that post-transcriptionally regulate gene expression through mRNA degradation or translational repression. miRNAs are key regulatory components of various cellular networks. Current evidence support that multiple mammalian genome-encoded miRNAs impact the cellular biology, including proliferation, apoptosis, differentiation, and tumorigenesis, by targeting specific subsets of mRNAs. This minireview is focused on the current themes underlying the interactions between miRNAs and their mRNA targets and pathways in prostate tumorigenesis and progression, and their potential clinical utility as biomarkers for prostate cancer.
Impact statement
The primary goal of this article was to review recent literature on miRNA biogenesis and further elaborate on the identity of newly discovered miRNAs and their potential functional significance in the complex biological network associated with prostate tumorigenesis and disease progression and as biomarkers for prostate cancer.
TurkbeyBBrownAMSankineniSWoodBJPintoPAChoykePL.Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA2016;
66:326–36
4.
AlloryYBeukersWSagreraAFlándezMMarquésMMárquezMvan der KeurKADyrskjotLLurkinIVermeijMCarratoALloretaJLorenteJACarrillo-de Santa PauEMasiusRGKogevinasMSteyerbergEWvan TilborgAAAbasCOrntoftTFZuiverloonTCMalatsNZwarthoffECRealFX.Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol2014;
65:360–6
5.
RenQLiangJWeiJBasturkOWangJDanielsGGellertLLLiYShenYOsmanIZhaoJMelamedJLeeP.Epithelial and stromal expression of miRNAs during prostate cancer progression. Am J Transl Res2014;
6:329–39
6.
OzenMCreightonCJOzdemirMIttmannM.Widespread deregulation of microRNA expression in human prostate cancer. Oncogene2008;
27:1788–93
7.
PorkkaKPPfeifferMJWalteringKKVessellaRLTammelaTLVisakorpiT.MicroRNA expression profiling in prostate cancer. Cancer Res2007;
67:6130–5
8.
LeissnerKHTisellLE.The weight of the human prostate. Scand J Urol Nephrol1979;
13:137–42
9.
LiljaH.Structure and function of prostatic- and seminal vesicle-secreted proteins involved in the gelation and liquefaction of human semen. Scand J Clin Lab Invest Suppl1988;
191:13–20
10.
TsukiseAYamadaK.Complex carbohydrates in the secretory epithelium of the goat prostate. Histochem J1984;
16:311–9
11.
BrawerMKPeehlDMStameyTABostwickDG.Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res1985;
45:3663–7
12.
NagleRBAhmannFRMcDanielKMPaquinMLClarkVACelnikerA.Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res1987;
47:281–6
13.
SherwoodERBergLAMitchellNJMcNealJEKozlowskiJMLeeC.Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol1990;
143:167–71
14.
LiuAYTrueLDLaTrayLNelsonPSEllisWJVessellaRLLangePHHoodLvan den EnghG.Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci U S A1997;
94:10705–10
15.
AbrahamssonPACockettATdi Sant'AgnesePA.Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl1998;
8:37–42
16.
di Sant'AgnesePA.Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer1992;
70:254–68
17.
di SAgnesePA.. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. Urology1998;
51:121–4
18.
Abate-ShenCShenMM.Molecular genetics of prostate cancer. Genes Dev2000;
14:2410–34
KoivistoPKononenJPalmbergCTammelaTHyytinenEIsolaJTrapmanJCleutjensKNoordzijAVisakorpiTKallioniemiOP.Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res1997;
57:314–9
21.
DenmeadeSRLinXSIsaacsJT.Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate1996;
28:251–65
22.
TanMHLiJXuHEMelcherKYongEL.Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin2015;
36:3–23
23.
FuWMadanEYeeMZhangH.Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta2012;
1825:140–52
24.
MassonSBahlA.Metastatic castrate-resistant prostate cancer: dawn of a new age of management. BJU Int2012;
110:1110–4
25.
DraismaGEtzioniRTsodikovAMariottoAWeverEGulatiRFeuerEde KoningH.Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst2009;
101:374–83
26.
ThompsonIMPaulerDKGoodmanPJTangenCMLuciaMSParnesHLMinasianLMFordLGLippmanSMCrawfordEDCrowleyJJColtmanCAJr.Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med2004;
350:2239–46
27.
AndrioleGLCrawfordEDGrubbRLBuysSS3rdChiaDChurchTRFouadMNIsaacsCKvalePARedingDJWeissfeldJLYokochiLAO'BrienBRagardLRClappJDRathmellJMRileyTLHsingAWIzmirlianGPinskyPFKramerBSMillerABGohaganJKProrokPC.Plco Project Team.
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst2012;
104:125–32
28.
SchröderFHHugossonJRoobolMJTammelaTLCiattoSNelenVKwiatkowskiMLujanMLiljaHZappaMDenisLJReckerFBerenguerAMäättänenLBangmaCHAusGVillersARebillardXvan der KwastTBlijenbergBGMossSMde KoningHJAuvinenAErspcI.Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009;
360:1320–8
29.
WrightJLLangePH.Newer potential biomarkers in prostate cancer. Rev Urol2007;
9:207–13
30.
LeeRCFeinbaumRLAmbrosV.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell1993;
75:843–54
31.
WightmanBHaIRuvkunG.Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell1993;
75:855–62
SassenSMiskaEACaldasC.MicroRNA: implications for cancer. Virchows Arch2008;
452:1–10
34.
KrutzfeldtJPoyMNStoffelM.Strategies to determine the biological function of microRNAs. Nat Genet2006;
38 Suppl:S141–9
35.
KoturbashIZempFJPogribnyIKovalchukO.Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis. Mutat Res2011;
722:94–105
36.
MacfarlaneLAMurphyPR.MicroRNA: biogenesis, function and role in cancer. Curr Genomics2010;
11:537–61
37.
BorchertGMLanierWDavidsonBL.RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol2006;
13:1097–101
38.
LeeYAhnCHanJChoiHKimJYimJLeeJProvostPRådmarkOKimSKimVN.The nuclear RNase III Drosha initiates microRNA processing. Nature2003;
425:415–9
39.
YiRQinYMacaraIGCullenBR.Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev2003;
17:3011–6
40.
ChendrimadaTPGregoryRIKumaraswamyENormanJCoochNNishikuraKShiekhattarR.TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature2005;
436:740–4
41.
BartelDP.MicroRNAs: target recognition and regulatory functions. Cell2009;
136:215–33
42.
HausserJZavolanM.Identification and consequences of miRNA-target interactions – beyond repression of gene expression. Nat Rev Genet2014;
15:599–612
43.
AmbrosVBartelBBartelDPBurgeCBCarringtonJCChenXDreyfussGEddySRGriffithsJSMarshallMMatzkeMRuvkunGTuschlT.A uniform system for microRNA annotation. RNA2003;
9:277–9
OsadaHTakahashiT.MicroRNAs in biological processes and carcinogenesis. Carcinogenesis2007;
28:2–12
46.
ChoWC.OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer2007;
6:60
47.
MoustafaAAZiadaMElshaikhADattaAKimHMorozKSrivastavSThomasRSilbersteinJLMopartyKSalemFEEl-HabitOHAbdel-MageedAB.Identification of microRNA signature and potential pathway targets in prostate cancer. Exp Biol Med (Maywood)2017;
242:536–46
48.
HoJYHsuRJWuCHLiaoGSGaoHWWangTHYuCP.Reduced miR-550a-3p leads to breast cancer initiation, growth, and metastasis by increasing levels of ERK1 and 2. Oncotarget2016;
7:53853–68
49.
BoslandMC.The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monograp2000;
27:39–66
50.
De MarzoAMPlatzEASutcliffeSXuJGrönbergHDrakeCGNakaiYIsaacsWBNelsonWG.Inflammation in prostate carcinogenesis. Nat Rev Cancer2007;
7:256–69
51.
ZhengTWangJChenXLiuL.Role of microRNA in anticancer drug resistance. Int J Cancer2010;
126:2–10
52.
CalinGADumitruCDShimizuMBichiRZupoSNochEAldlerHRattanSKeatingMRaiKRassentiLKippsTNegriniMBullrichFCroceCM.Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A2002;
99:15524–9
53.
Abd ElmageedZYYangYThomasRRanjanMMondalDMorozKFangZRezkBMMopartyKSikkaSCSartorOAbdel-MageedAB.Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells2014;
32:983–97
54.
ShiXBXueLMaAHTepperCGKungHJWhiteRW.miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate2011;
71:538–49
55.
BuddWTSeashols-WilliamsSJClarkGCWeaverDCalvertVPetricoinEDragoescuEAO'HanlonKZehnerZE.Dual action of miR-125b as a tumor suppressor and OncomiR-22 promotes prostate cancer tumorigenesis. PLoS One2015;
10:e0142373
56.
Seashols-WilliamsSJBuddWClarkGCWuQDanielRDragoescuEZehnerZE.miR-9 acts as an OncomiR in prostate cancer through multiple pathways that drive tumour progression and metastasis. PLoS One2016;
11:e0159601
57.
FletcherCEDartDASita-LumsdenAChengHRenniePSBevanCL.Androgen-regulated processing of the oncomir miR-27a, which targets prohibitin in prostate cancer. Hum Mol Genet2012;
21:3112–27
58.
HsuTIHsuCHLeeKHLinJTChenCSChangKCSuCYHsiaoMLuPJ.MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo. Oncogenesis2014;
3:e99
59.
NørgaardMJensenAØJacobsenJBCetinKFryzekJPSørensenHT.Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol2010;
184:162–7
60.
HanMLiuMWangYChenXXuJSunYZhaoLQuHFanYWuC.Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN. PLoS One2012;
7:e39520
61.
LuMHHuangCCPanMRChenHHHungWC.Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clin Cancer Res2012;
18:6416–25
62.
LouWLiuJGaoYZhongGChenDShenJBaoCXuLPanJChengJDingBFanW.MicroRNAs in cancer metastasis and angiogenesis. Oncotarget2017;
8:115787–802
63.
GururajanMJossonSChuGCLuCLLuYTHagaCLZhauHELiuCLichtermanJDuanPPosadasEMChungLW.miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res2014;
20:6559–69
64.
JossonSGururajanMHuPShaoCChuGYZhauHELiuCLaoKLuCLLuYTLichtermanJNandanaSLiQRogatkoABerelDPosadasEMFazliLSareenDChungLW.miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res2014;
20:4636–46
65.
SiuMKTsaiYCChangYSYinJJSuauFChenWYLiuYN.Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene2015;
34:4767–76
66.
LiuLZLiCChenQJingYCarpenterRJiangYKungHFLaiLJiangBH.MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1alpha expression. PLoS One2011;
6:e19139
67.
ReisSTPontes-JuniorJAntunesAADall'OglioMFDipNPasserottiCCRossiniGAMoraisDRNesrallahAJPiantinoCSrougiMLeiteKR.miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol2012;
12:14
68.
DoldiVCallariMGiannoniED'AiutoFMaffezziniMValdagniRChiarugiPGandelliniPZaffaroniN.Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. Oncotarget2015;
6:31441–60
TaoJWuDXuBQianWLiPLuQYinCZhangW.microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep2012;
27:1967–75
71.
BertoliGCavaCCastiglioniI.MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer. IJMS2016;
17:421
72.
CaiZKChenQChenYBGuMZhengDCZhouJWangZ.microRNA-155 promotes the proliferation of prostate cancer cells by targeting annexin 7. Mol Med Rep2015;
11:533–8
73.
WangZXueYWangPZhuJMaJ.MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncol Rep2016;
35:2733–42
74.
KumarBLupoldSE.MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery. Asian J Androl2016;
18:559–67
75.
YangYJiaDKimHAbd ElmageedZYDattaADavisRSrivastavSMorozKCrawfordBEMopartyKThomasRHudsonRSAmbsSAbdel-MageedAB.Dysregulation of miR-212 promotes castration resistance through hnRNPH1-mediated regulation of AR and AR-V7: implications for racial disparity of prostate cancer. Clin Cancer Res2016;
22:1744–56
76.
DingHYQianWQXuJ.MicroRNA-146b acts as a potential tumor suppressor in human prostate cancer. J BUON2016;
21:434–43
77.
FuQLiuXLiuYYangJLvGDongS.MicroRNA-335 and -543 suppress bone metastasis in prostate cancer via targeting endothelial nitric oxide synthase. Int J Mol Med2015;
36:1417–25
78.
ZhuQLiHLiYJiangL.MicroRNA-30a functions as tumor suppressor and inhibits the proliferation and invasion of prostate cancer cells by down-regulation of SIX1. Hum Cell2017;
30:290–9
79.
LiuYNYinJJAbou-KheirWHynesPGCaseyOMFangLYiMStephensRMSengVSheppard-TillmanHMartinPKellyK.MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene2013;
32:296–306
80.
RenDWangMGuoWHuangSWangZZhaoXDuHSongLPengX.Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Cell Tissue Res2014;
358:763–78
81.
ChenQZhaoXZhangHYuanHZhuMSunQLaiXWangYHuangJYanJYuJ.MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2. Mol Carcinog2015;
54:1292–300
82.
GandelliniPFoliniMLongoniNPennatiMBindaMColecchiaMSalvioniRSupinoRMorettiRLimontaPValdagniRDaidoneMGZaffaroniN.miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res2009;
69:2287–95
83.
GandelliniPProfumoVCasamicheleAFendericoNBorrelliSPetrovichGSantilliGCallariMColecchiaMPozziSDe CesareMFoliniMValdagniRMantovaniRZaffaroniN.miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. Cell Death Differ2012;
19:1750–60
84.
XuBWangNWangXTongNShaoNTaoJLiPNiuXFengNZhangLHuaLWangZChenM.MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer. Prostate2012;
72:1171–8
85.
ChangYSChenWYYinJJSheppard-TillmanHHuangJLiuYN.EGF receptor promotes prostate cancer bone metastasis by downregulating miR-1 and activating TWIST1. Cancer Res2015;
75:3077–86
86.
LiuYNYinJBarrettBSheppard-TillmanHLiDCaseyOMFangLHynesPGAmeriAHKellyK.Loss of androgen-regulated microRNA 1 activates SRC and promotes prostate cancer bone metastasis. Mol Cell Biol2015;
35:1940–51
87.
LinZYHuangYQZhangYQHanZDHeHCLingXHFuXDaiQSCaiCChenJHLiangYXJiangFNZhongWDWangFWuCL.MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer2014;
135:541–50
88.
SiuMKAbou-KheirWYinJJChangYSBarrettBSuauFCaseyOChenWYFangLHynesPHsiehYYLiuYNHuangJKellyK.Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget2014;
5:3770–84
89.
ValentinoAReclusaPSireraRGiallombardoMCampsCPauwelsPCrispiSRolfoC.Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer. Clin Transl Oncol2017;
19:651–7
90.
RaposoGStoorvogelW.Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol2013;
200:373–83
91.
ValadiHEkströmKBossiosASjöstrandMLeeJJLötvallJO.Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol2007;
9:654–9
92.
WeberJABaxterDHZhangSHuangDYHuangKHLeeMJGalasDJWangK.The microRNA spectrum in 12 body fluids. Clin Chem2010;
56:1733–41
93.
RodríguezMBajo-SantosCHessvikNPLorenzSFrommBBergeVSandvigKLinēALlorenteA.Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer2017;
16:156
94.
EndzeliņšEMelneVKalniņaZLietuvietisVRiekstiņaULlorenteALinēA.Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review. Mol Cancer2016;
15:41
95.
FilellaXFojL.Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci2016;
17:pii:E1784
96.
YuDCLiQGDingXWDingYT.Circulating microRNAs: potential biomarkers for cancer. IJMS2011;
12:2055–63
97.
MitchellPSParkinRKKrohEMFritzBRWymanSKPogosova-AgadjanyanELPetersonANoteboomJO'BriantKCAllenALinDWUrbanNDrescherCWKnudsenBSStirewaltDLGentlemanRVessellaRLNelsonPSMartinDBTewariM.Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A2008;
105:10513–8
98.
LodesMJCaraballoMSuciuDMunroSKumarAAndersonB.Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One2009;
4:e6229
99.
BraseJCJohannesMSchlommTFälthMHaeseASteuberTBeissbarthTKunerRSültmannH.Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer2011;
128:608–16
100.
HuangXYuanTLiangMDuMXiaSDittmarRWangDSeeWCostelloBAQuevedoFTanWNandyDBevanGHLongenbachSSunZLuYWangTThibodeauSNBoardmanLKohliMWangL.Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol2015;
67:33–41
101.
SamsonovRShtamTBurdakovVGlotovATsyrlinaEBersteinLNosovAEvtushenkoVFilatovMMalekA.Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic. Prostate2016;
76:68–79
102.
HaldrupCKosakaNOchiyaTBorreMHøyerSOrntoftTFSorensenKD.Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Deliv and Transl Res2014;
4:19–30
103.
TiberioPCallariMAngeloniVDaidoneMGAppiertoV.Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int2015;
2015:731479
104.
KoshiolJWangEZhaoYMarincolaFLandiMT.Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev2010;
19:907–11
